ENTITY
BeiGene

BeiGene (6160 HK)

303
Analysis
Health CareChina
BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.
more
Refresh
bullishNetEase Inc
05 May 2020 18:43

NetEase HK Listing - Early Look - Follow the Leader

NetEase Inc (NTES US) has filed confidentially for a secondary listing in Hong Kong, as per media reports. It aims to raise around US$1-2bn. In our...

Logo
490 Views
Share
29 Apr 2020 11:19

JD.com HK Listing - Early Look - Getting the Ball Rolling

IFR announced overnight that JD.com Inc (ADR) (JD US) has filed confidentially for a secondary listing in Hong Kong. The deal is expected to be...

Logo
565 Views
Share
21 Mar 2020 21:00

InnoCare Pharma: Trading Debut, Valuation Scenario Analysis

InnoCare Pharma Ltd (9969 HK) is a pre-revenue biotech company with a focus on research and development, manufacturing and commercialisation of...

Logo
338 Views
Share
13 Mar 2020 14:16

InnoCare (诺诚健华) IPO: Bifurcated Book, Update of Our View

InnoCare launched the book building on March 11th to raise up to USD 288 million to list in Hong Kong. Book building will end on March 16...

Logo
439 Views
Share
11 Mar 2020 16:48

InnoCare Pharma IPO: Valuation Easy to Swallow

InnoCare Pharma Ltd (9969 HK) is a pre-revenue biotech company with a focus on research and development, manufacturing and commercialisation of...

Logo
471 Views
Share
x